Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 11Terminated 5Unknown 4Recruiting 4Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 79Sarcoma 16Gastrointestinal 8Dermatologic 6Tumor-Agnostic 4NET 4Lymphoid 4Endocrine 4Thoracic 3Other solid neoplasm 3Genitourinary 3Gynecologic 2Breast 1

Conditions

Lymphoma 3Recurrence 1Neoplasms 1Lymphoma, Follicular 1Glioblastoma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 170Rituximab 143Specimen Handling 82venetoclax 79fludarabine 78Vincristine 69obinutuzumab 67Doxorubicin 66Prednisone 65Biopsy 64Magnetic Resonance Spectroscopy 62zanubrutinib 52Lenalidomide 52Dexamethasone 49Methotrexate 43Cytarabine 43blinatumomab 40acalabrutinib 37Immunotherapy, Adoptive 37Bendamustine Hydrochloride 37Etoposide 32fludarabine phosphate 31ibrutinib 28glofitamab 28polatuzumab vedotin 26pirtobrutinib 24orelabrutinib 24Gemcitabine 23Injections 21Mercaptopurine 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Temozolomide × Lymphoid × Clear all
NCT05765812 2026-05-28

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Debiopharm International SA

Phase 1/2 Recruiting
116 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT07015242 2026-03-24

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 2 Recruiting
65 enrolled
Lymphoid

Lymphoma

NCT06475235 2026-02-20

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Dana-Farber Cancer Institute

Phase 1 Recruiting
15 enrolled
Lymphoid

Lymphoma

NCT06208657 2026-01-28

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Australian & New Zealand Children's Haematology/Oncology Group

Phase 1/2 Recruiting
90 enrolled
CNSLymphoid

Lymphoma, Neoplasms, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡